Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc. is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon vaccines, delivered using the company's proprietary electroporation technology, are generating best-in-class immune responses, with therapeutic T cells exceeding other technologies. Inovio's lead vaccine, a therapeutic against HPV-caused precancers and cancers, is in phase 2. Other phase 1 and preclinical programs target prostate, breast and lung cancers as well as HIV, influenza, malaria and hepatitis. Roche and Inovio have an exclusive worldwide partnership to develop and commercialize Inovio's DNA immunotherapies for prostate cancer and hepatitis B.

Expert Comments:

Jefferson Research (11/27/15)
"Inovio Pharmaceuticals Inc. is showing strong earnings quality and cash flow quality, and valuation suggests a lower amount of price risk. . .the company's stock deserves a Hold rating. The primary reason the overall rating improved during the last quarter was an improvement in the balance sheet rating due to strengthening receivable and inventory positions. Another factor in the upgraded overall rating was an improved operating efficiency rating."

Yi Chen, H.C. Wainwright & Co. (11/20/15)
"GLS-5300 is the DNA vaccine for Middle East respiratory syndrome (MERS) co-developed by Inovio Pharmaceuticals Inc. and GeneOne. . .yesterday, the FDA cleared the clinical trial of this MERS vaccine. The trial is expected to initiate by 2015E. . .this vaccine development update once again reflects the capital efficient approach of Inovio to move its multiple pipeline projects forward."

Jason McCarthy, Maxim Group (11/9/15)
"Inovio Pharmaceuticals Inc. reported Q3/15 with revenues of $24M, which includes $15M of the upfront payment ($27M total) from MedImmune. The company reported EPS of $0.08 and ended the period with $171M in cash, which should be sufficient to fund operations into 2018."

Jason McCarthy, Maxim Group (11/6/15)
"Inovio Pharmaceuticals Inc. announced that INO-3112 (combination of VGX-3100 and DNA-based interleukin-12) generated human papillomavirus (HPV) 16/18 CD8 T-cell responses in all 10 evaluable head and neck cancer patients in the phase 1/2a. . .this is continued positive news for the company and shows that the VGX-3100 platform targeting HPV-driven diseases and cancers may be successful in multiple indications."

"We remodeled VGX-3100, Inovio's DNA immunotherapy for HPV-driven cancers and pre-cancers (cervical dysplasia), which includes INO-3112. INO-3112, a combination of VGX-3100 and DNA-based IL-12 is now partnered to MedImmune. Our model reflects all the milestones, the payments associated with those milestones, and the royalty structure that could be achieved in the market for human papillomavirus (HPV)-driven head-and-neck cancers. We have seen such compelling data from VGX-3100 in cervical dysplasia caused by HPV that we felt comfortable reducing the discount rate used to model free cash flow. We have seen robust immune responses that include histological regression of cervical intraepithelial neoplasia (CIN)-2/3 back to CIN-1 or better—essentially healthy cells with no dysplasia. That also made us comfortable walking down the discount rate. These factors could potentially drive the stock price higher. . .we believe that Inovio is going to start its Phase 3 trial with VGX-3100 in cervical dysplasia. INO-3112 will also get going. In addition, we expect data from the company's Ebola consortium and the Phase 1 trial in healthy volunteers, as well as data on other pipeline projects. . ." read more >

Yi Chen, H.C. Wainwright & Co. (9/22/15)
"Inovio Pharmaceuticals Inc. recently announced the publication of Phase 2b trial results of VGX-3100 in treating women with high grade cervical neoplasia against the human papillomavirus (HPV) 16 and 18 in a peer-reviewed article in The Lancet. Inovio's VGX-3100 is the first therapy to demonstrate that activated killer T cells induced in the body have the power to clear neoplastic lesions as well as the virus. It could present a safe and non-surgical therapeutic option for CIN2/3."

More Expert Comments

Experts Following This Company

Yi Chen, Managing Director of Equity Research – H.C. Wainwright & Co.
Charles Duncan, Managing Director, Senior Biotechnology Analyst – Piper Jaffray & Co.
Christopher James, Managing Director, Senior Equity Research Analyst – Brinson Patrick Securities Corporation
Jason Kolbert, Senior Analyst – Maxim Group
Kevin McCarthy, Co-Managing Partner – Kayne Anderson MLP Investment Co.
Jason McCarthy, Analyst – Maxim Group
Jason Russ, Author Seeking Alpha
Ross Silver, Co-Founder and Principal Analyst – Vista Partners
Jill Wahleithner, Fund Manager – Wasatch Funds
George Zavoico, Senior Equity Analyst – JonesTrading International Services LLC

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.